Head-to-head evidence
Perseris vs Risperidone (Rykindo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Perseris
Marketed by Indivior Pharmaceuticals, Inc.
NCT02109562 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.
Risperidone (Rykindo)
Marketed by Luye Pharma Group
NCT02055287 · Phase 1 · completed
A non-randomized, open-label, four-dose pharmacokinetic study of Rykindo in 36 participants. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Perseris's landscape · Risperidone (Rykindo)'s landscape